Short answer
Aclaris Therapeutics, Inc. (ACRS) filed an 8-K current report with the SEC on October 27, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Equity offering targets approximately $46.7 million net proceeds for Aclaris.
Aclaris Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Equity offering targets approximately $46.7 million net proceeds for Aclaris
- Issuance comprises 7,785,714 common shares and pre-funded warrants for 6,500,000 shares
- Offering prices: $3.50 per share and $3.49999 per warrant
- Pre-funded warrants exercisable indefinitely at $0.00001 per share, creating substantial potential dilution
- Closing expected October 28, 2026, subject to customary conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aclaris Therapeutics, Inc. 8-K filings
Get the next ACRS 8-K as it lands
Follow ACRS for push alerts, or ask the research agent what this filing means.